Migraine Clinical Trial
Official title:
Mindfulness Based Stress Reduction for Adults With Migraines: A Pilot Study
Verified date | March 2013 |
Source | Brigham and Women's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This proposal describes a randomized controlled pilot trial investigating feasibility, safety, and migraine frequency in patients with migraines who undergo an 8 week mindfulness based stress reduction (MBSR) program compared to a wait-list control group.
Status | Completed |
Enrollment | 19 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of migraine (International Classification of Headache Disorders-II);21 - 4-14 days with migraines/month - =one year of migraines - =18 years - Able and willing to attend weekly sessions and willing to participate in daily mindfulness assignments, up to 30-45 min/day - Agreeable to participate and to be randomized to either group - Fluent in English (since the treatment groups will be run in English) - Good general health with no additional diseases expected to interfere with the study Exclusion Criteria: - Current regular meditation/yoga practice - Any major systemic illness or unstable medical or psychiatric condition (e.g. suicide risk) requiring immediate treatment or that could lead to difficulty complying with the protocol - Diagnosis of medication overuse headache (International Classification of Headache Disorders-II);19 - Current or planned pregnancy or breastfeeding - New prophylactic migraine medicine started within 4 weeks of the screening visit - Unwilling to maintain stable current doses of migraine medicines for the duration of trial - Failure to complete baseline diary recordings of migraine activity and medication use |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Migraine frequency from Baseline | Change in the number of migraines per month from baseline(tracked with headache logs) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in self-efficacy from baseline | Change in self-efficacy from baseline(Headache Management Self-Efficacy Scale) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in perceived stress from baseline | Change in Perceived stress scale from baseline | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in migraine-related disability/impact from baseline | Change in migraine-related disability/impact from baseline(one month MIDAS and HIT-6) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in anxiety from baseline | Change in anxiety from baseline (state-trait anxiety measure) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in depression from baseline | Change in depression from baseline(PHQ-9) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in mindfulness from baseline | Change in mindfulness from baseline(Five facet mindfulness scale) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Qualitative interviews | Participants will be interviewed qualitatively | immediately post-intervention | |
Secondary | Change in migraine severity from baseline | Change in Migraine intensity (1-10) tracked via headache logs from baseline | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in Migraine duration from baseline | Length of migraines (tracked via headache logs) | baseline, immediately post-intervention, 4 weeks post-intervention | |
Secondary | Change in quality of life from baseline | Change in Migraine specific quality of life from baseline | baseline, immediately post-intervention, 4 weeks post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |